Preclinical transfusion-dependent humanized mouse model of \( \beta \) thalassemia major

Yongliang Huo,1 Sean C. McConnell,1 and Thomas M. Ryan1

1Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham

A preclinical humanized mouse model of \( \beta \) thalassemia major or Cooley anemia (CA) was generated by targeted gene replacement of the mouse adult globin genes in embryonic stem cells. The mouse adult \( \alpha \) and \( \beta \) globin genes were replaced with adult human \( \alpha \) globin genes (\( \alpha ^{2}x^{1} \)) and a human fetal to adult hemoglobin (Hb)–switching cassette (\( \gamma ^{HPFH}6\beta ^{2} \)), respectively. Similar to human infants with CA, fully humanized mice survived postnatally by synthesizing predominantly human fetal Hb, HbF (\( \alpha ^{2}\gamma ^{2}z^{2} \)), with a small amount of human minor adult Hb, HbA2 (\( \alpha ^{2}\beta ^{2} \)). Completion of the human fetal to adult Hb switch after birth resulted in severe anemia marked by erythroid hyperplasia, ineffective erythropoiesis, hemolysis, and death. Similar to human patients, CA mice were rescued from lethal anemia by regular blood transfusion. Transfusion corrected the anemia and effectively suppressed the ineffective erythropoiesis, but led to iron overload. This preclinical humanized animal model of CA will be useful for the development of new transfusion and iron chelation regimens, the study of iron homeostasis in disease, and testing of cellular and genetic therapies for the correction of thalassemia.

From www.bloodjournal.org by guest on October 15, 2017. For personal use only.
Methods

Generation of humanized γ\(^{\text{HPFH}}\)β\(^{0}\) knockin mice

A targeting construct, γ\(^{\text{HPFH}}\)β\(^{0}\), was built in pBluescript vector (Stratagene, La Jolla, CA) containing from 5′ to 3′ a phosphoglycerate kinase (pgk) promoter driving thymidine kinase, 1.7 kb of mouse homology upstream of the mouse β\(^{\text{maj}}\) globin gene (HindIII fragment), 4.7-kb human γ\(^{\text{globin gene fragment} (\text{Accession U01317: 39 013-43 728}), 2.9-kb}\) human δ globin gene fragment (U01317: 54 336-57 279), 4.1-kb human β globin gene fragment (U01317: 61 320-65 426), a pgk promoter driving hygromycin (pgk-hyg) resistance gene flanked by 2 loxP sites, and 7 kb of mouse homology downstream of the mouse β\(^{\text{min}}\) globin gene (BamHI fragment). The hereditary persistence of fetal Hb (HPFH) mutation, guanine (G) to adenine (A) transition at position −117 of the human γ globin gene, and the human β globin gene mutation, G to A transition in the first base of intervening sequence 1 (IVS1.1 G to A), were introduced by polymerase chain reaction (PCR). The plasmid was linearized by Nsil digestion before electroporation into the mouse embryonic stem (ES) cell line. The ES cells were selected in hygromycin B (125 μg/mL) and ganciclovir (1 mM) in ES cell media (Dulbecco modification of Eagle medium, 15% fetal bovine serum [HyClone, Logan, UT], 1× nucleosides, 2 mM L-glutamine, 1× nonessential amino acids, 50 IU/mL penicillin, 50 μg/mL streptomycin, 0.1 mM β-mercaptoethanol, and 1000 UI/mL leukemia inhibitory factor). After selection, DNA from drug-resistant ES cell colonies was screened by PCR to identify the homologous recombinants. Mice were cloned by injecting the ES cells into 8-cell stage C57BL/6J (The Jackson Laboratory, Bar Harbor, ME) blastocysts.28,19 that were transferred into the uteri of outbred CD1 (Charles River Laboratories, Wilmington, MA) pseudopregnant recipient mice. The cloned mice were interbred to hCMV-Cre transgenic mice20 and human α2ε1 globin knockin (KI) mice (T.M.R., unpublished data, December 2004) and to delete the hygromycin marker gene and generate doubly heterozygous γ\(^{\text{HPFH}}\)β\(^{0}\) and α2ε1 KI mice. Fully humanized CA mice were produced by breeding 2 heterozygous KI mice. All procedures were approved by the University of Alabama at Birmingham (UAB) Institutional Animal Care and Use Committee.

High-performance liquid chromatography analysis of Hb chains

Hemolysates are prepared by lysing washed RBCs in hemolyse buffer (5 mM phosphate, 0.5 mM EDTA [ethylene-diaminetetraacetic acid], pH 7.4), adding NaCl to 1%, and removing RBC membranes by centrifugation. A linear gradient of increasing acetonitrile with 0.1% trifluoroacetic acid at a 1.0 mL/minutes flow rate was used to separate human and mouse globin chains on a reverse-phase C4 column (Vydac, Hesperia, CA) on a Surveyor high-performance liquid chromatography (HPLC) instrument (Thermo Scientific, Waltham, MA).

Hematologic indices and histopathology

Peripheral blood was collected from anesthetized mice into Microtainer tubes (BD Biosciences, Franklin Lakes, NJ). Blood smears were stained by Dip-Quick staining kit (Jorgensen Laboratories, Loveland, CO). MCHC and HGB were determined by a Hemavet 1700 (Drew Scientific, Waterbury, CT) hematology analyzer. Pack cell volume (PCV) was measured in a JorVet 1503 (Jorgensen Laboratories) microhematocrit centrifuge. Hb concentrations were determined after conversion to cyanmethemoglobin by lysing RBCs in Drabkin reagent (Sigma-Aldrich, St Louis, MO), removing insoluble RBC membranes by centrifugation, measuring the absorbance at 540 nm on a spectrophotometer, and comparing with Hb standards. Reticulocyte counts were determined by flow cytometry after staining with thiazole orange.21 Tissues were fixed in 70% alcoholic formalin, embedded in paraffin, sectioned, and stained with hematoxylin-eosin by standard methods at the UAB Comparative Pathology Laboratory (CPL). Liver iron was stained by Prussian Blue. All slides were analyzed on Nikon Eclipse TE2000-U microscope (Nikon, Tokyo, Japan). Images were taken on Nikon Coolpix 990 digital camera and processed by Adobe Photoshop CS version 8.0 imaging software (Adobe Systems, San Jose, CA).

Blood transfusion and tissue iron quantification

Weekly transfusion therapy began 2 days after birth. Peripheral blood from green fluorescent protein (GFP) transgenic mice (C57BL/6-transgenic (UBC-GFP) 30Sca/J, stock no. 004353; The Jackson Laboratory) was collected from anesthetized mice into Microtainer EDTA collection tubes (BD Biosciences). Enucleated GFP+ RBCs were collected after Ficoll gradient separation, followed by 3 washes in cold PBS. The first 2 transfusions were through superficial temporal (facial) vein and intraperitoneal cavity, respectively. Mice older than 3 weeks were transfused by retro-orbital injection. For hypertransfusion, 300 to 400 μL blood was transfused, and half dose was used for hypotransfusion. Mice were killed at 8 weeks of age. Livers and hearts were preserved in 30% formalin and dried, and the nonheme iron concentrations were determined colorimetrically.22

Results

Establishment of humanized γ\(^{\text{HPFH}}\)β\(^{0}\) mouse model of CA

Previous studies showed that a humanized mouse model of CA that contained a human fetal to adult Hb-switching cassette could survive to birth solely upon human fetal Hb, but died shortly thereafter due to severe anemia.17 By incorporating an HPFH γ globin allele to further delay the fetal to adult Hb switch and including the human δ globin gene for the production of minor human fetal HbA2, the postnatal survival of humanized CA mice was extended to make them more amenable for study. Humanized γ\(^{\text{HPFH}}\)β\(^{0}\) CA mice were generated by targeted gene replacement of the adult mouse β globin genes, β\(^{\text{maj}}\) and β\(^{\text{min}}\), with human fetal γ\(^{\text{HPFH}}\) globin and human adult δ and β globin genes by homologous recombination in ES cells (Figure 1A). The human γ\(^{\text{HPFH}}\) globin allele contains the Greek nondeletional HPFH promoter mutation at nucleotide position −117 shown to elevate γ globin gene expression levels in both humans and transgenic mice.23-26

The human adult globin alleles contain a wild-type δ globin gene and a mutant β globin allele found in the Mediterranean population.27,28 This nonfunctional β globin gene has a mutant splice donor site (IVS1.1 G to A) that produces several short-lived mRNAs from cryptic splice donor sites and no functional protein in mice.17 Heterozygous γ\(^{\text{HPFH}}\) β\(^{0}\) mice were generated from correctly targeted ES cells, and liver DNA was analyzed by Southern blot to confirm the targeted replacement of the mouse β globin genes (Figure 1B). Heterozygous γ\(^{\text{HPFH}}\) β\(^{0}\) mice were bred with human adult α2ε1 KI mice (generated by targeted gene replacement of both adult mouse α globin genes; T.M.R., unpublished data, December 2004) and human wild-type γβ A KI mice29 to generate mice living on 100% human Hb. Fully humanized compound heterozygous γ\(^{\text{HPFH}}\)β\(^{0}\)/γβ A mice (β thalassemia minor) were bled weekly to analyze their fetal to adult Hb switch (Figure 2A). At birth compound heterozygous mice had 64% (±1.7%); mean ± [SEM], n = 8) human γ globin chains, 36% (±1.7%) human β globin chains, and no measureable human δ globin chains. Similar to newborn humans, the high fetal globin chain levels present at birth were gradually replaced by increasing levels of adult globins. The β-like globin chain composition stabilizes by 8 weeks of age with fetal γ globin chains reduced to 4.9% (±0.8%) and the adult β and δ globin chains levels increased to 90.5% (±0.7%) and 4.6% (±0.2%), respectively.
breeding to CRE recombinase transgenic mice. 20 (B) Southern blot confirmation of gene, and a 10.3-kb fragment from the human globin KI allele. The 3'/H11032 fragment from the wild-type allele and a 7.9-kb fragment from the human globin KI targeted gene replacement of the adult mouse phenotype, all of the littermate controls, which include mice expired as early as 1 day after birth, 1 CA mouse survived into birth (Figure 2B). Sixty-five percent of CA mice died within a period of development, the humanized homozygous HPFH and generated a Hb-switching pattern that more closely mimics that seen in thalassemia patients.30 The lifespan of humanized homozygous CA mice increased their survival beyond birth and generated a Hb-switching pattern that more closely mimics that seen in thalassemia patients.30

Humanized γHPFHβ0 CA mice have a β thalassemia major phenotype

Concomitant with the decrease in fetal Hb during the postnatal period of development, the humanized homozygous γHPFHβ0 CA mice (β thalassemia major) became severely anemic. At the time of their euthanasia, CA mice had a marked reduction in their RBC counts, PCVs, and Hb levels compared with littermate HbA controls (Table 1). This anemia induced a massive erythroid hyperplasia in the humanized CA mice. The spleen, a normal site of stress erythropoiesis in mice, becomes greatly expanded in models of hemolytic anemia. The percentage of cells in the bone marrow and spleen that express the erythroid-specific cell-surface antigen Ter119 was 60% and 83%, respectively, in CA mice compared with 40% and 50% in control animals (Figure 3A and Table 2). In addition to the fractional increase in erythroid cells in the spleen, there was also an average 14-fold increase in the size of the spleen (Table 1), resulting in an overall 23-fold increase in splenic erythroid cells in CA mice. This splenomegaly was characterized by a loss of the normal architecture of red (erythroid) and white (lymphoid) pulp regions that were replaced with mostly early stage erythroblasts (Figures 3A, 4, and Table 2). Extramedullary hematopoiesis was observed as clusters of erythroblasts throughout the liver (Figure 4). The RBC morphology in peripheral blood smears was typical of severe β thalassemia. Marked anisopoikilocytosis, polychromatophilia, spherocytosis, and numerous nucleated erythroblasts were present (Figure 4). There was a doubling of the RBC distribution width, RDW, due to the mixture of large nascent reticulocytes with small mature spherocytes (Table 1). Excess precipitated α globin chains were observed after vital staining with crystal violet (Figure S1, available on the Blood website; see the Supplemental Materials link at the top of the online article). In the absence of any therapeutic intervention, CA mice died due to their lethal anemia before weaning age (Figure 2B).
Table 1. Hematology of humanized HbA control, β thalassemia minor, and β thalassemia major mice before and after transfusion

<table>
<thead>
<tr>
<th>Human Hb mice</th>
<th>n</th>
<th>RBC, 10⁶/µL</th>
<th>Hb, g/dL</th>
<th>PCV, %</th>
<th>Retic, %</th>
<th>RDW, %</th>
<th>Spleen, % of BW</th>
</tr>
</thead>
<tbody>
<tr>
<td>HbA control</td>
<td>9</td>
<td>10.9 (± 0.3)</td>
<td>13.6 (± 0.1)</td>
<td>44.8 (± 0.4)</td>
<td>2.8 (± 0.2)</td>
<td>19.6 (± 0.2)</td>
<td>0.35 (± 0.02)</td>
</tr>
<tr>
<td>β thalassemia minor</td>
<td>10</td>
<td>11.8 (± 0.2)*</td>
<td>12.7 (± 0.3)*</td>
<td>42.0 (± 0.7)*</td>
<td>4.1 (± 0.3)*</td>
<td>20.2 (± 0.3)*</td>
<td>0.53 (± 0.04)*</td>
</tr>
<tr>
<td>β thalassemia major untransfused CA</td>
<td>9</td>
<td>2.5 (± 0.3)**</td>
<td>3.0 (± 0.4)**</td>
<td>15.0 (± 1.9)**</td>
<td>72.1 (± 2.2)**</td>
<td>38.5 (± 2.4)**</td>
<td>5.1 (± 1.5)**</td>
</tr>
<tr>
<td>β thalassemia major hypertransfused CA</td>
<td>5</td>
<td>9.8 (± 0.5)*</td>
<td>15.1 (± 0.6)*</td>
<td>42.2 (± 1.8)*</td>
<td>ND</td>
<td>16.0 (± 0.2)**</td>
<td>0.79 (± 0.07)**</td>
</tr>
<tr>
<td>β thalassemia major hypotransfused CA</td>
<td>5</td>
<td>5.9 (± 0.1)**</td>
<td>7.4 (± 0.4)**</td>
<td>25.8 (± 0.7)**</td>
<td>ND</td>
<td>18.4 (± 0.5)*</td>
<td>4.1 (± 0.4)**</td>
</tr>
</tbody>
</table>

Genotypes of human Hb mice are as follows: HbA (α2β1), β thalassemia minor (α2β1/α2β1), and β thalassemia major (α2β1/α2β1). Mice are analyzed 8 weeks after birth, except the untransfused CA mice, which are analyzed at the time of their euthanasia (age of 19 ± 6 days). Values represent mean ± SEM. Statistical significances are determined for the β thalassemic major and minor mice compared with the HbA control mice. *P values were calculated by 2-tailed unpaired Student t test.

RBC indicates red blood cell; Hb, hemoglobin; PCV, packed cell volume; Retic, reticulocyte; RDW, red cell distribution width; BW, body weight; ND, not determined; and n.s., not significant.

**P < .05.

**P < .0001.

Marked ineffective erythropoiesis and hemolysis in humanized γHPFHβα CA mice

Because the premature destruction of erythroid progenitors in the bone marrow (ineffective erythropoiesis) and erythrocytes from the circulation (hemolysis) are hallmarks of β thalassemia, their roles in the progression of anemia in the humanized CA mice were analyzed. Erythroid progenitors in the bone marrow and spleen of wild-type and homozygous γHPFHβα CA mice were stained with fluorescently labeled antibodies to the erythroid antigen Ter119, and the transferrin receptor, CD71, to distinguish pro-, early, and late erythroblasts, as previously described.31 Ter119+ erythroblasts (region I: CD71HIGH, Ter119LOW) and early erythroblasts (regions II and III) in the bone marrow of CA mice. However, in the CA spleen, only the late erythroblasts (region III) had significantly increased levels of annexin V+ cells compared with controls. These data demonstrates a marked expansion of progenitors that was skewed toward earlier erythroblasts.

In humans, free α globin chains in differentiating thalassemic erythroblasts can cause premature cell death by apoptosis.1-3 Apoptosis of early and late erythroblasts was analyzed by flow cytometry after binding to fluorescent-labeled annexin V (Figure 3B and Table 3).32 There was a significant increase in annexin V+ early and late erythroblasts (regions II and III) in the bone marrow of CA mice. However, in the CA spleen, only the late erythroblasts (region III) had significantly increased levels of annexin V+ cells compared with controls. These data

Figure 3. Erythroid hyperplasia, ineffective erythropoiesis, and hemolysis in humanized γHPFHβα CA mice. (A) Erythroid hyperplasia in the bone marrow and spleen of CA mice was measured by flow cytometry. Bone marrow and spleen cells from age- and sex-matched CA and wild-type mice were stained with fluorescently labeled antibodies to the erythroid antigen Ter119 and transferrin receptor CD71 and fluorescent-labeled annexin V. Dead cells were excluded by 7-aminoactinomycin D (7AAD) staining. The percentages of proerythroblasts (region I: CD71HIGH, Ter119LOW), early erythroblasts (region II: CD71+, Ter119+), late erythroblasts (region III: CD71+, Ter119+), and total Ter119+ erythroblasts (total Ter119+) in the bone marrow and spleen are shown in Table 2. Erythroid populations of humanized HbA mice (α2β1/α2β1) and C57BL/6J wild-type mice did not differ significantly (data not shown). (B) Demonstration of ineffective erythropoiesis in CA mice by apoptosis of erythroid progenitors by annexin V-binding assay.32 Representative histograms are shown of annexin V staining of early (region II) and late (region III) erythroblasts in CA and control mouse bone marrow and spleen cells from panel A. No antibody control samples were stained with all the antibodies in panel A, except annexin V. Annexin V+ cell ratios are quantified in Table 3. Annexin V+ erythroblasts of humanized HbA mice (α2β1/α2β1) and C57BL/6J wild-type mice did not differ significantly (data not shown). (C) Bilirubin levels increased significantly in untransfused CA mice compared with age- and sex-matched wild-type control mice, indicating increased hemolysis in CA mice. Bilirubin levels returned to control levels in hypertransfused, but not hypotransfused CA mice. *P < .05; **P < .0001; n = 3 in each group.
demonstrate increased levels of ineffective erythropoiesis caused by apoptosis of early and late erythroblasts in the bone marrow and late erythroblasts in the spleen of CA mice.

Hemolysis of RBCs was another cause of anemia in humanized CA mice. Peripheral blood smears showed numerous damaged RBCs, intracellular inclusions, and reticulocytes (Figures 4, S1). Elevated reticulocytosis with decreased RBC count, a direct indicator of hemolysis in β thalassemia, was confirmed by flow cytometry of thiazole orange-stained blood.²¹ In CA mice, the reticulocyte count was 72.1% (± 2.2%) compared with 2.8% (± 0.2%) in γβ⁴γβ⁷α¹ literate control mice (Table 1). Another indicator of hemolysis is increased plasma bilirubin, a product of Hb degradation. The total plasma bilirubin levels in CA mice compared with control mice increased from 0.2 mg/dL to 18.4 (± 0.8) mg/dL. Direct bilirubin levels increased from 0.1 mg/dL in wild-type mice to 2.8 (± 0.8) mg/dL in CA mice. Hence, indirect bilirubin increased from 0.1 mg/dL to 15.6 gm/dL, approximately 150-fold in CA mice (Figure 3C). These data demonstrate that hemolysis contributes to the severe anemia in humanized CA mice.

<table>
<thead>
<tr>
<th>Tissue</th>
<th>Cells (region)</th>
<th>Control mouse</th>
<th>CA mice</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bone marrow</td>
<td>Proerythroblasts</td>
<td>0.13 (± 0.03)</td>
<td>0.82 (± 0.21)</td>
<td>.0188</td>
</tr>
<tr>
<td></td>
<td>Early erythroblasts</td>
<td>27.9 (± 5.6)</td>
<td>56.0 (± 3.1)</td>
<td>.0046</td>
</tr>
<tr>
<td></td>
<td>Late erythroblasts</td>
<td>11.9 (± 2.9)</td>
<td>4.0 (± 0.8)</td>
<td>.04</td>
</tr>
<tr>
<td></td>
<td>Total Ter119</td>
<td>39.7 (± 4.2)</td>
<td>60.1 (± 2.6)</td>
<td>.0059</td>
</tr>
<tr>
<td>Spleen</td>
<td>Proerythroblasts</td>
<td>0.10 (± 0.04)</td>
<td>0.70 (± 0.16)</td>
<td>.0126</td>
</tr>
<tr>
<td></td>
<td>Early erythroblasts</td>
<td>15.6 (± 6.7)</td>
<td>74.9 (± 5.6)</td>
<td>.0005</td>
</tr>
<tr>
<td></td>
<td>Late erythroblasts</td>
<td>34.1 (± 3.6)</td>
<td>8.3 (± 1.9)</td>
<td>.0007</td>
</tr>
<tr>
<td></td>
<td>Total Ter119</td>
<td>49.7 (± 3.4)</td>
<td>83.2 (± 6.9)</td>
<td>.0048</td>
</tr>
</tbody>
</table>

Statistical significances were determined for the CA mice compared with control mice. Erythroid populations of humanized HbA mice (α²α¹α²α¹γ²γ²) and C57BL/6J control mice do not differ significantly (data not shown). Percentages are mean (± SEM), n = 4 in each group. P values were calculated by 2-tailed unpaired Student t test.

Rescue of humanized γ⁴β⁷β³ CA mice from lethal anemia by transfusion therapy

Regular lifelong blood transfusion therapy is essential for the survival and improved quality of life of β thalassemia major patients. An important goal of transfusion therapy is to maintain Hb levels high enough to alleviate anemia, suppress ineffective erythropoiesis, and allow for normal growth and development, while simultaneously limiting adverse transfusion reactions and toxicity from iron overload.

Humanized γ⁴β⁷β³ CA mice were given blood transfusions to rescue them from lethal anemia. Two groups of CA mice were transfused weekly for a total of 8 weeks with fresh, leukocyte reduced, packed RBCs from GFP transgenic mouse blood donors.¹⁵ Hypotransfused mice received enough donor blood to maintain Hb levels at approximately 14 g/dL. Hypotransfused mice were transfused to raise Hb levels only to approximately 7 g/dL (Figure 5A). Both groups of CA mice receiving transfusions had stable Hb and γ⁴β⁷β³ RBC chimerism levels by 1 month of age (Figure 5A,B). Transfused CA mice survived well beyond the lethal end point of untransfused CA mice (compare age in Figure 2B with Figure 5).

After 8 weeks of therapy, the anemia in both groups of transfused CA mice was markedly improved compared with untransfused CA mice. RBC indices in hypotransfused mice were similar to wild-type controls (Table 1). Less than 1% of the

Figure 4. Histopathology of blood, spleen, and liver of humanized HbA control and CA mice before and after transfusion. Peripheral blood smears of untransfused CA mice exhibit severe anemia compared with HbA littermate control mice. There are significant numbers of reticulocytes, circulating erythroblasts, and microcytic, hypochromic, and fragmented RBCs in untransfused CA mouse blood. In addition, the normal structure of red pulp and white pulp in the spleen is absent. In the liver of untransfused CA mice, there are extensive clusters of extramedullary hemopoiesis and increased iron staining. In contrast, the hypotransfused CA mouse has a normal peripheral blood smear and greatly improved histology similar to the HbA control, except excess iron is present in the liver. Hypotransfused CA mouse is still anemic, have significant numbers of erythroblasts and thalassemic RBCs in the blood, and have a histopathology similar to the untransfused CA mouse. All mice are 8 weeks of age, except for the untransfused CA mouse, which is only 2 weeks old. Scale bars: blood smear, 10 μm; spleen, 100 μm; liver (low power), 50 μm; liver (high power), 10 μm; liver iron, 50 μm.

Table 2. Percentages of erythroid progenitor populations in the bone marrow and spleen of humanized CA and control mice by flow cytometry

<table>
<thead>
<tr>
<th>Tissue</th>
<th>Cells Region</th>
<th>Control mouse</th>
<th>CA mice</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bone marrow</td>
<td>Proerythroblasts</td>
<td>0.13 (± 0.03)</td>
<td>0.82 (± 0.21)</td>
<td>.0188</td>
</tr>
<tr>
<td></td>
<td>Early erythroblasts</td>
<td>27.9 (± 5.6)</td>
<td>56.0 (± 3.1)</td>
<td>.0046</td>
</tr>
<tr>
<td></td>
<td>Late erythroblasts</td>
<td>11.9 (± 2.9)</td>
<td>4.0 (± 0.8)</td>
<td>.04</td>
</tr>
<tr>
<td></td>
<td>Total Ter119</td>
<td>39.7 (± 4.2)</td>
<td>60.1 (± 2.6)</td>
<td>.0059</td>
</tr>
<tr>
<td>Spleen</td>
<td>Proerythroblasts</td>
<td>0.10 (± 0.04)</td>
<td>0.70 (± 0.16)</td>
<td>.0126</td>
</tr>
<tr>
<td></td>
<td>Early erythroblasts</td>
<td>15.6 (± 6.7)</td>
<td>74.9 (± 5.6)</td>
<td>.0005</td>
</tr>
<tr>
<td></td>
<td>Late erythroblasts</td>
<td>34.1 (± 3.6)</td>
<td>8.3 (± 1.9)</td>
<td>.0007</td>
</tr>
<tr>
<td></td>
<td>Total Ter119</td>
<td>49.7 (± 3.4)</td>
<td>83.2 (± 6.9)</td>
<td>.0048</td>
</tr>
</tbody>
</table>

Table 3. Percentages of annexin V⁺ staining erythroid progenitors in the bone marrow and spleen of humanized CA versus control mice

<table>
<thead>
<tr>
<th>Tissue</th>
<th>Cells Region</th>
<th>Control mouse</th>
<th>CA mice</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bone marrow</td>
<td>Early erythroblasts (II)</td>
<td>13.9 (± 3.3)</td>
<td>33.7 (± 3.5)</td>
<td>.0059</td>
</tr>
<tr>
<td></td>
<td>Late erythroblasts (III)</td>
<td>1.8 (± 0.3)</td>
<td>50.0 (± 2.5)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Spleen</td>
<td>Early erythroblasts (II)</td>
<td>13.6 (± 4.5)</td>
<td>20.9 (± 4.8)</td>
<td>.0099</td>
</tr>
<tr>
<td></td>
<td>Late erythroblasts (III)</td>
<td>0.9 (± 0.3)</td>
<td>53.2 (± 1.6)</td>
<td>&lt;.0001</td>
</tr>
</tbody>
</table>

Statistical significances were determined for the CA mice compared with control mice. Annexin V⁺ erythroid populations of humanized HbA mice (α²α¹α²α¹γ²γ²β³) and C57BL/6J control mice do not differ significantly (data not shown). Percentages are mean (± SEM), n = 4 in each group. P values were calculated by 2-tailed unpaired Student t test.

For personal use only.on October 15, 2017. by guest
circulating RBCs in hypertransfused CA mice was derived from endogenous erythropoiesis, suggesting that the erythropoietic activity was effectively suppressed (Figure 5B). Suppression of endogenous ineffective erythropoiesis was confirmed in the bone marrow, where the percentage of Ter119+ cells was decreased 63% from untransfused CA mice (60%-22%) and 33% from wild-type controls (33% to 22%, Figure 6A). No extramedullary hematopoiesis was found in the livers of hypertransfused CA mice, splenomegaly was markedly reduced with restoration of normal red and white pulp, and plasma bilirubin levels returned to normal (Figures 3C, 4).

In contrast, hypotransfused CA mice were still anemic with low RBC counts, Hb levels, and PCVs compared with wild-type control animals (Table 1). Hypotransfused CA mice still had approximately 20% endogenous thalassemic RBCs in the peripheral blood (GPP−, Figure 5B) with numerous circulating erythroblasts (Figure 4) and elevated plasma bilirubin (Figure 3C), suggesting continued robust endogenous erythropoietic activity and hemolysis. Expanded ineffective erythropoiesis was still evident in the bone marrow, where the percentage of erythroid cells was 70% above wild-type mice and only slightly decreased from untransfused CA mice (Figure 6A). The histopathologic phenotype of hypotransfused mice was similar to 2-week-old untransfused CA mice. There were continued erythroid hyperplasia, ineffective erythropoiesis, and extramedullary hematopoiesis (Figure 4).

Because mammals have no active mechanism for removal of excess iron, regular transfusion therapy can lead to increased iron stores in the tissues. Both transfusion regimens led to increased Prussian blue iron staining in the liver similar to untransfused CA mice (Figure 4). Mouse liver and heart storage iron from both transfused groups was quantified. Compared with humanized γβ0/γβ4 littermate control mice, the liver storage iron concentration increased significantly under both transfusion regimens.

However, there was no increase in the heart storage iron concentration after 8 weeks of transfusion therapy (Figure 6B).

**Discussion**

This study describes a mouse model of β thalassemia major that has numerous improvements over previous models. This novel CA model is heritable; survives postnatally solely on human HbF and HbA2; has marked erythroid hyperplasia, ineffective erythropoiesis, reticulocytosis, and hemolysis; and rescue from death by regular transfusion results in iron overload. Because all these characteristics are shared with β thalassemia major patients, this humanized CA model is suitable for both basic and preclinical studies.

The major weakness of earlier models of CA was their early prenatal death due to differences in the developmental timing of Hb switching in humans and mice. Mice switch from primitive embryonic globins directly to definitive adult globins early in fetal life. Therefore, deletions of the adult mouse globin locus also switch fetal to adult Hb too early in development. Similarly, transgenic mice that contain large portions of the human β globin locus also switch fetal to adult Hb too early in development. However, linked human γ and β globin transgenes with the intergenic region deleted exhibit a delay in the fetal to adult Hb switch. Humanized mice containing such transgenes have high levels of human HbF at birth. Recently, we incorporated such a delayed γ to β Hb switching cassette (γβ) directly into the mouse β globin locus replacing the murine adult β globin genes. Humanized mice with a delayed Hb-switching γβ0 cassette are born solely with human HbF in their RBCs, but expired within hours due to anemia. By incorporating an HPFH mutation into the γ globin gene promoter and the minor adult δ globin gene in the γHPFH/γβ0 KI cassette, the humanized CA mice reported in this study have an extended postnatal lifespan compared with the previous γβ0 CA mouse model.
A simple lifespan comparison of mice (2 years) with humans (70 years) suggests each day of life in the mouse would represent approximately 35 days in humans. Using this simple age-scaling model, a median lifespan of 14 days in the humanized CA mice represents 490 days in humans or approximately 16 months. This is approximately the same timeframe that infants with CA become severely anemic and require blood transfusions for survival. The similarity in timing of disease onset between humans and CA mice allows the study of the effects of anemia on disease progression during development and the testing of therapeutic strategies designed to cure β thalassemia in humans before onset of severe disease.

Whereas there are numerous nondeletional HPFH mutations in humans that cause asymptomatic elevation of fetal Hb through adulthood,25,40-43 the Greek nondeletional HPFH – 117 mutation was used to generate this humanized model of CA.25 It is possible that other HPFH mutations in similar context would also generate viable humanized CA mice whose postnatal survival correlates with γ globin expression level. Some may even live into adulthood.

The level of minor adult HbA2 is usually elevated in heterozygous β thalassemia, and its measurement is an important diagnostic tool for identifying carriers of β thalassemia.

There is a clear postnatal Hb switch from γ to δ in the compound heterozygous γHPFHβγ/βA mouse (Figure 2A), and the final adult HbA2 level of 4.6% (± 0.2%) is comparable with that measured in human β thalassemia trait patients.

The HbA2 levels could potentially be greater at birth if a wild-type rather than an HPFH γ globin promoter had been used in the KI cassette because the HPFH promoter is most likely delaying the Hb switch. Regardless, the presence of even small amounts of δ globin chains would beneficially reduce excess α globin chains in the thalassemic erythrocytes in this humanized CA model.


Acknowledgments

We thank Jin-Xiang Ren for her expert technical assistance. We thank Mary Hamilton, Maya Spivey, and Albert Tousson from the UAB CPL and High-Resolution Imaging Facility cores for their technical assistance. We thank the Cooley’s Anemia Foundation’s Request for Application for Translational Research in Adult Thalassemia for support. We thank Joseph Ruisi, UNICO, and the Thalassemia-Cooley’s Anemia Group at UAB.

This work was supported by National Institutes of Health grants R01 HL072351 and R01 HL073440 (T.M.R.), and T32 GM008111 (S.C.M.).

Authorship

Contribution: Y.H. designed and performed experiments, analyzed research, made figures, and wrote the paper; S.C.M. performed experiments and analyzed research; and T.M.R. designed and performed experiments, analyzed research, and wrote the paper.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Dr Thomas M. Ryan, Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, 1918 University Blvd, MCLM 566A, Birmingham, AL 35294; e-mail: tryan@uab.edu.

References


Preclinical transfusion-dependent humanized mouse model of β thalassemia major

Yongliang Huo, Sean C. McConnell and Thomas M. Ryan